Literature DB >> 16096642

Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.

Heike Laman1, Juan M Funes, Hongtao Ye, Stephen Henderson, Laura Galinanes-Garcia, Eiji Hara, Phillip Knowles, Neil McDonald, Chris Boshoff.   

Abstract

D cyclins (D1, D2 and D3) and their catalytic subunits (cyclin-dependent kinases cdk4 and cdk6) have a facilitating, but nonessential, role in cell cycle entry. Tissue-specific functions for D-type cyclins and cdks have been reported; however, the biochemical properties of these kinases are indistinguishable. We report that an F box protein, Fbxo7, interacted with cellular and viral D cyclins and distinguished among the cdks that bind D-type cyclins, specifically binding cdk6, in vitro and in vivo. Fbxo7 specifically regulated D cyclin/cdk6 complexes: Fbxo7 knockdown decreased cdk6 association with cyclin and its overexpression increased D cyclin/cdk6 activity and E2F activity. Fbxo7 interacted with p27, but its enhancement of cyclin D/cdk6 activity was p21/p27 independent. Fbxo7 overexpression transformed murine fibroblasts, rendering them tumorigenic in athymic nude mice. Transformed phenotypes were dependent on cdk6, as knockdown of cdk6 reversed them. Fbxo7 was highly expressed in epithelial tumors, but not in normal tissues, suggesting that it may have a proto-oncogenic role in human cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096642      PMCID: PMC1201355          DOI: 10.1038/sj.emboj.7600775

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

Review 1.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

Review 2.  Ub on the move.

Authors:  Natalia Shcherbik; Dale S Haines
Journal:  J Cell Biochem       Date:  2004-09-01       Impact factor: 4.429

3.  Physical interaction of mammalian CDC37 with CDK4.

Authors:  K Dai; R Kobayashi; D Beach
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

Review 4.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.

Authors:  M Hall; G Peters
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

Review 5.  D-type cyclins.

Authors:  C J Sherr
Journal:  Trends Biochem Sci       Date:  1995-05       Impact factor: 13.807

Review 6.  Principles of CDK regulation.

Authors:  D O Morgan
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

7.  Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.

Authors:  L Stepanova; X Leng; S B Parker; J W Harper
Journal:  Genes Dev       Date:  1996-06-15       Impact factor: 11.361

Review 8.  Cyclin D1 as a cellular proto-oncogene.

Authors:  S Bates; G Peters
Journal:  Semin Cancer Biol       Date:  1995-04       Impact factor: 15.707

9.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.

Authors:  E E Schmidt; K Ichimura; G Reifenberger; V P Collins
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  D-type cyclin-dependent kinase activity in mammalian cells.

Authors:  H Matsushime; D E Quelle; S A Shurtleff; M Shibuya; C J Sherr; J Y Kato
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

View more
  46 in total

Review 1.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

2.  The F-box protein FBXO25 promotes the proteasome-dependent degradation of ELK-1 protein.

Authors:  Felipe R Teixeira; Adriana O Manfiolli; Cláudia S Soares; Munira M A Baqui; Tie Koide; Marcelo D Gomes
Journal:  J Biol Chem       Date:  2013-08-12       Impact factor: 5.157

3.  Expression, purification and crystallization of the FP domain of the human F-box protein Fbxo7.

Authors:  Jinsai Shang; Guan Wang; Yang Yang; Xiaolan Huang; Zhihua Du
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-09-28

4.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays.

Authors:  Seyedmehdi Shojaee; Farzad Sina; Setareh Sadat Banihosseini; Mohammad Hossein Kazemi; Reza Kalhor; Gholam-Ali Shahidi; Hossein Fakhrai-Rad; Mostafa Ronaghi; Elahe Elahi
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

5.  Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice.

Authors:  Siv Vingill; David Brockelt; Camille Lancelin; Lars Tatenhorst; Guergana Dontcheva; Christian Preisinger; Nicola Schwedhelm-Domeyer; Sabitha Joseph; Miso Mitkovski; Sandra Goebbels; Klaus-Armin Nave; Jörg B Schulz; Till Marquardt; Paul Lingor; Judith Stegmüller
Journal:  EMBO J       Date:  2016-08-05       Impact factor: 11.598

Review 6.  Regulation of Normal and Malignant Hematopoiesis by FBOX Ubiquitin E3 Ligases.

Authors:  R Willow Hynes-Smith; Karli J Wittorf; Shannon M Buckley
Journal:  Trends Immunol       Date:  2020-11-04       Impact factor: 16.687

7.  Characterization of the porcine FBX07 gene: the first step towards generation of a pig model for Parkinsonian pyramidal syndrome.

Authors:  Knud Larsen; Christian Bendixen
Journal:  Mol Biol Rep       Date:  2011-05-25       Impact factor: 2.316

Review 8.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 9.  Roles of F-box proteins in cancer.

Authors:  Zhiwei Wang; Pengda Liu; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

10.  Common and specific roles of the related CDK inhibitors p27 and p57 revealed by a knock-in mouse model.

Authors:  Etsuo Susaki; Keiko Nakayama; Lili Yamasaki; Keiichi I Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.